Cancer Immunotherapy and Experimental Therapeutics - T32

癌症免疫疗法和实验疗法 - T32

• 批准号: 9974498
• 负责人: Eduardo V Davila
• 金额: $ 34.53万
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-07-08 至 2024-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9974498
• 关键词: Investigational Therapies; cancer immunotherapy

ABSTRACT A significant advance in cancer, still a major cause of morbidity and mortality in the US, has been the discovery of immune-directed therapy. This is a rapidly changing field that will require future clinician researchers to draw upon a skillset that is quite distinct from current investigation and practice, as host factors take a dominant role over traditional, anatomical-driven parameters. The goal of this proposed T32 program is to train future oncology clinical providers and researchers in the most advanced and promising forms of immune-directed and cell therapy, by integrating those newly required skills into a training plan that addresses those unique needs. New challenges include a multitude of new agents under development, new mechanisms of action, a distinct toxicity profile mostly consisting of immune/autoimmune side effects, and the lack of patient selection or predictive markers for these therapies. The opportunity is to invent Developmental Therapeutics (DT) strategies that maximally exploit the power of immune-based therapy. Our vision for this proposed T32 is to create a training program and environment that will provide essential skills to clinical trainees while simultaneously providing them with the opportunity to contribute to developing the next generation of cancer therapies. To implement this program, we will draw upon the scientific and translational strengths of the University of Colorado School of Medicine (UCSOM). Indeed, the UCSOM has a strong history of basic immune research (discovery of IL-1 and STING), as well as allergy and autoimmunity research with world- class asthma (National Jewish), and diabetes (Barbara Davis) centers. The UCSOM has provided $20M to launch the Human Immunology and Immunotherapy Initiative (HI3), and has supported the creation of in-house facilities to produce clinical-grade cell therapy products, enabling cutting edge therapies like CAR T-cells. To bridge the bench-to-bedside gap, substantial efforts have been devoted to create advanced, humanized mouse models. Additionally, the UCSOM is a leader in oncology clinical translation with a prestigious DT program, and it was this focus in early DT that allowed us to become leaders in immune and cell therapy. The UCSOM has created a Personalized Medicine Center, designed to facilitate scientific/clinical programs seeking to develop patient-specific therapies. Finally, to link all of the scientific potential in these resources to the delivery of patient care, the medical center has invested over $50M to enhance informatics capabilities enabling data mining and research initiatives towards optimizing clinical decision-making and new therapy development. The sum of the resources outlined above provide the foundation for creating a unique training program, focused on preparing clinical investigators and physician scientists to discover the next generation of immunotherapies. This program will be uniquely tailored to adapt to the specific training requirements of clinical fellows, to guarantee top level research training while maintaining the quality of their core clinical experience. The program will be designated as the Cancer Immunotherapy and Experimental Therapeutics Program (CIETP).

抽象的 癌症的重大进展，仍然是美国发病率和死亡率的主要原因，是发现 免疫定向治疗。这是一个快速变化的领域，需要未来的临床研究人员绘制 在与当前的调查和实践完全不同的技能方面，作为宿主因素占据主导地位 超过传统的解剖学驱动参数。该提议的T32计划的目标是培训未来 肿瘤学临床提供者和研究人员是最先进，最有前途的免疫指导形式的 通过将这些新必需的技能纳入满足这些独特需求的培训计划中，通过将这些新必需的技能整合在一起。 新的挑战包括正在开发的众多新代理，新的行动机制，一个独特的 毒性特征主要由免疫/自身免疫性副作用组成，缺乏患者选择或 这些疗法的预测标记。机会是发明发育治疗学（DT） 最大程度利用免疫治疗能力的策略。我们对此提出的T32的愿景是 创建培训计划和环境，将为临床学员提供重要技能 同时为他们提供有助于发展下一代癌症的机会 疗法。为了实施此计划，我们将借鉴 科罗拉多大学医学院（UCSOM）。确实，UCSOM有很强的基本历史 免疫研究（发现IL-1和Sting），以及与世界的过敏和自身免疫研究 类哮喘（国家犹太人）和糖尿病（芭芭拉·戴维斯）中心。 UCSOM已向2000万美元提供 发起人类免疫学和免疫疗法计划（HI3），并支持内部的创建 生产临床级细胞疗法产品的设施，从而实现诸如汽车T细胞之类的尖端疗法。到 桥梁到床位的差距，已经大力努力创建高级，人性化的鼠标 型号。此外，UCSOM是肿瘤学临床翻译领域的领导者，具有著名的DT计划，并且 正是早期DT的重点使我们成为免疫和细胞疗法的领导者。 UCSOM具有 创建了一个个性化的医学中心，旨在促进寻求发展的科学/临床计划 特定于患者的疗法。最后，将这些资源中的所有科学潜力联系起来 患者护理，医疗中心已投资超过5000万美元，以增强信息学能力，从而实现数据 采矿和研究计划，以优化临床决策和新的治疗开发。这 上面概述的资源的总和为创建独特的培训计划提供了基础，重点是 准备临床研究人员和医师科学家发现下一代免疫疗法。 该计划将是针对适应临床研究员的特定培训要求而量身定制的 确保高层研究培训，同时保持其核心临床经验的质量。这 计划将被指定为癌症免疫疗法和实验治疗计划（CIETP）。